Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Noninvasive Test Monitors Bladder Cancer Recurrence

By LabMedica International staff writers
Posted on 18 Feb 2015
The results of a blinded, multicenter clinical study that used noninvasive technology to detect bladder cancer recurrence in patients with a history of the disease have been announced. More...


The blinded clinical study was conducted in nine medical centers, where urine samples from 217 subjects with a history of bladder cancer were tested. The study population included 121 healthy subjects and 96 patients currently suffering from the disease.

The CellDetect test (Micromedic Technologies Ltd.; Tel Aviv, Israel) successfully identified cancerous cells in urine samples, with reported sensitivity of 84.4% and specificity of 82.7% for the study's primary endpoint. The results of the CellDetect urine test were compared with results from biopsy or cystoscopy, in cases where biopsies were not performed. The results also indicated that the negative predictive value (NPV) was 98.5%. In addition to its high sensitivity for advanced stage tumors and high-grade malignancy, the test was also found to exhibit high sensitivity for early stage tumors and low-grade malignancies which are difficult to identify using other noninvasive tests currently available on the market.

The secondary endpoint showed that the sensitivity of other noninvasive comparator tests, urine cytology, BTA stat (Polymedco; Redmond, WA, USA) and NMP22 BladderCheck (Alere; Waltham, MA, USA) was 50.0%, 68.8% and 17.4%, respectively. These findings indicate that the method is adequately sensitive for the purpose of accurate and early detection of the recurrence of the disease.

Ofer Yossepowitch. MD, Head of the Uro-Oncology Service at Rabin Medical Center (Petach Tikva, Israel), said, “The study results are encouraging. The accuracy of this novel assay appears to be superior over any available noninvasive test, suggesting a potential to supplant some or all of the cystoscopies required for bladder cancer surveillance. This is indeed great news for patients with history of bladder cancer, which may change their management.”

Related Links:

Micromedic Technologies Ltd. 
Polymedco
Alere 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.